IRIS
PALMIERI, RAFFAELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.961
AS - Asia 1.556
EU - Europa 1.488
Continente sconosciuto - Info sul continente non disponibili 362
SA - Sud America 278
AF - Africa 33
OC - Oceania 7
Totale 7.685
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.851
IT - Italia 773
SG - Singapore 660
CN - Cina 221
BR - Brasile 207
RU - Federazione Russa 187
HK - Hong Kong 176
BD - Bangladesh 144
VN - Vietnam 122
IE - Irlanda 95
DE - Germania 68
NL - Olanda 66
CA - Canada 65
GB - Regno Unito 64
JP - Giappone 61
FR - Francia 53
IN - India 43
FI - Finlandia 42
SE - Svezia 27
ID - Indonesia 23
AR - Argentina 22
PL - Polonia 22
ES - Italia 20
MX - Messico 20
CO - Colombia 15
KR - Corea 15
TH - Thailandia 13
AT - Austria 11
ZA - Sudafrica 11
BE - Belgio 10
IQ - Iraq 10
PH - Filippine 10
VE - Venezuela 10
PK - Pakistan 9
SA - Arabia Saudita 9
EC - Ecuador 8
IR - Iran 7
TR - Turchia 7
AU - Australia 6
CZ - Repubblica Ceca 6
GR - Grecia 6
PY - Paraguay 6
UA - Ucraina 6
MY - Malesia 5
CR - Costa Rica 4
HR - Croazia 4
KE - Kenya 4
LT - Lituania 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
EG - Egitto 3
LU - Lussemburgo 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
ET - Etiopia 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
IL - Israele 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
NP - Nepal 2
PS - Palestinian Territory 2
RO - Romania 2
SD - Sudan 2
SV - El Salvador 2
TW - Taiwan 2
UY - Uruguay 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BY - Bielorussia 1
CM - Camerun 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
HT - Haiti 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
KW - Kuwait 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
PT - Portogallo 1
Totale 7.324
Salva come PNG Salva come JPEG
Città #
Singapore 401
Ashburn 354
Houston 338
Wilmington 331
San Jose 293
Rome 210
Hong Kong 170
Council Bluffs 160
Chandler 153
New York 139
Dallas 108
Beijing 104
Fairfield 92
Los Angeles 87
Santa Clara 76
Dublin 71
Milan 65
Tokyo 57
Engelhard 49
Ho Chi Minh City 45
Buffalo 43
Woodbridge 43
Medford 41
North Bergen 40
The Dalles 40
Ann Arbor 37
Seattle 36
Cambridge 34
Boardman 32
Denver 26
Moscow 26
Lauterbourg 23
São Paulo 23
Brooklyn 22
Chicago 21
Lawrence 21
Orem 21
Lappeenranta 19
Atlanta 18
Hanoi 18
Warsaw 18
Jakarta 17
Montreal 17
Phoenix 17
San Diego 17
Helsinki 16
Bologna 15
Creede 15
Nuremberg 15
Seoul 15
Toronto 15
Munich 14
Frankfurt am Main 12
Turin 12
Bang Bai Mai 11
London 11
Stockholm 11
Amsterdam 10
Bari 10
Colorado Springs 10
Brussels 9
Billings 8
Redondo Beach 8
Bay Shore 7
Charlotte 7
Da Nang 7
Dearborn 7
Florence 7
Johannesburg 7
Las Vegas 7
Philadelphia 7
Rio de Janeiro 7
San Francisco 7
Baghdad 6
Mexico City 6
Naples 6
Porto Alegre 6
Pune 6
Quito 6
Shenzhen 6
Asunción 5
Biên Hòa 5
Bogotá 5
Boston 5
Brno 5
Chennai 5
Columbus 5
Haiphong 5
Hyderabad 5
Marseille 5
Miami 5
Milwaukee 5
Mumbai 5
Parma 5
Richmond 5
Roebling 5
Tolentino 5
Washington 5
Bari Sardo 4
Calgary 4
Totale 4.400
Salva come PNG Salva come JPEG
Nome #
DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE 405
Case report: A Saprochaete clavata (Magnusiomyces clavatus) severe infection effectively treated with granulocyte transfusion in a young patient with myeloid sarcoma 268
Clinical relevance of an objective - limit of detection - limit of quantification - based flow cytometry approach for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial 254
An evaluation of enasidenib for the treatment of acute myeloid leukemia 252
ACUTE LEUKEMIA AND LATENT TUBERCULOSIS INFECTION IN ITALY: QUANTIFERON-TB TEST SCREENING IN A LOW TUBERCULOSIS INCIDENCE COUNTRY 242
Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness 228
WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine 227
The Efficacy and Safety of Lenalidomide plus Rituximab in an Orbital Relapse of Diffuse Large B-Cell Lymphoma 210
Primary Cutaneous Anaplastic Large Cell Lymphoma of the Oral Cavity Successfully Treated with Brentuximab Vedotin 200
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia 176
FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS 172
Current strategies for detection and approach to measurable residual disease in Acute Myeloid Leukemia 167
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 160
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia 154
Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation 153
Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in {SARS}-{CoV}-2 infected patients: a single center study 151
A complex clinical presentation of ultra-high risk acute promyelocytic leukemia: A case report and insights on management 150
Use of Primary Prophylaxis with G-CSF in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy Does Not Affect Quality of Response 148
An Polycythemia Vera Evolve from Acute Myeloid Leukemia? Report of a Case Showing a Simultaneous Minor JAK2 V617F Mutated Clone 148
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML 145
Acute Leukemia diagnosis during the Covid-19 pandemic 145
Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML 121
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia 120
Validation of the T-Lymphocyte Subset Index (TLSI) as a Score to Predict Mortality in Unvaccinated Hospitalized COVID-19 Patients 118
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 115
Ponatinib and Risk of Thrombotic Events: In Vitro Study on Platelet Functions 115
A fatal case of peritonitis due to colonic localization of acute myeloid leukemia 115
Leukemia cutis in a patient with acute myeloid leukemia undergoing Azacitidine-Venetoclax: case presentation and review of the literature 113
Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience 110
Literature review and expert opinion on the treatment of high-risk acute myeloid leukemia in patients who are eligible for intensive chemotherapy 106
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION 104
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 102
Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia 102
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias 101
Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia 100
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) 99
The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19 95
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations 93
Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy 92
In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia 90
Pulmonary function testing for fitness assessment in asymptomatic adults with newly diagnosed acute myeloid leukemia 88
Fitness in acute myeloid leukemia, state of the art and future directions 87
Editorial: Measurable residual disease in hematologic malignancies 84
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm 83
Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms 82
Incidence and Characteristics of Perianal Infections in CPX-351-Treated AML Patients 81
Real World Study on the Best CPX‐351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation 78
Time for Dynamic Assessment of Fitness in Acute Myeloid Leukemia 75
Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial 75
FITNESS ASSESSMENT IN ACUTE MYELOID LEUKEMIA: RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF EUROPEAN LEUKEMIA NET 72
Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not? 71
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis 70
Risk-adapted MRD-directed therapy for young acute myeloid leukemia adults: 6-year update of the GIMEMA AML1310 trial 69
The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis 58
APL‐like subset within NPM1‐mutated AML: A distinct immunophenotype correlating with early vascular complications 51
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 50
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia 41
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 41
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial 31
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm 30
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study 26
Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML 26
Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts 25
Allogeneic stem cell transplantation in patients with a prior history of prostate cancer 24
Health-related quality of life of patients with acute myeloid leukemia and myelodysplastic syndromes/neoplasms treated with decitabine: a systematic literature review 22
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation 21
De novo JAK2-mutated acute myeloid leukaemia: Clinical outcomes and molecular features 20
Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial 19
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 19
Totale 7.685
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022297 0 0 0 3 9 45 16 17 52 31 20 104
2022/2023575 54 38 47 40 49 93 86 50 67 19 19 13
2023/2024532 26 8 168 9 20 103 17 45 30 16 20 70
2024/20251.239 48 168 114 75 25 78 132 62 195 113 138 91
2025/20262.911 238 127 324 241 335 107 301 318 277 285 202 156
2026/20271.176 178 165 449 384 0 0 0 0 0 0 0 0
Totale 7.685